Pulmonary embolism; This literature-non-study case was reported in a literature article and describes the occurrence of PULMONARY EMBOLISM (Pulmonary embolism) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.        No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced PULMONARY EMBOLISM (Pulmonary embolism) (seriousness criteria hospitalization and medically significant). At the time of the report, PULMONARY EMBOLISM (Pulmonary embolism) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.   For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.  Company Comment: This is a literature non-study case concerning a patient of unknown age and gender, with no reported medical history, who experienced the serious (due to medically significant and hospitalization) unexpected, AESI of Pulmonary embolism, which occurred within 42 days after the first dose of mRNA-1273 vaccine. The outcome was not reported. No further clinical information was available for medical review. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This report concerns patient who experienced Pulmonary embolism after first dose of moderna vaccine.  Concomitant and treatment medications were not reported.  This study described simultaneous vaccination (SV) with primary series COVID-19 vaccines and assess 23 pre-specified health outcomes following SV among persons aged =5 years in the Vaccine Safety Datalink (VSD).  This study utilized VSD's COVID-19 vaccine surveillance data from December 11, 2020-May 21, 2022. Analyses assessed frequency of SV.   Rate ratios (RRs) were estimated by Poisson regression when the number of outcomes was =5 across both doses, comparing outcome rates between COVID-19 vaccinees receiving SV and COVID-19 vaccinees receiving no SV in the 1-21 days following COVID-19 vaccine dose 1 and 1-42 days following dose 2 by SV type received ("All SV", "Influenza SV", "Non-influenza SV").  The most frequent simultaneous vaccines were influenza, HPV, Tdap, and meningococcal. Outcomes following SV with COVID-19 vaccines were rare (total of 56 outcomes observed after dose 1 and dose 2).   Adjusted RRs for the All Simultaneous Vaccines" group were statistically significantly elevated for appendicitis in the 121 days following COVID-19 vaccine dose 1. Of the nine appendicitis cases, one patient received Moderna COVID-19 vaccine.  Authors concluded that overall, the combined pre-specified health outcomes observed among persons who received simultaneous vaccines with COVID-19 vaccine were also rare and not at a statistically significantly different rate compared with those who did not receive simultaneous vaccination with the COVID-19 vaccine. Statistically significant adjusted rate ratios were observed for some individual outcomes (appendicitis, convulsions/seizures, and Bell's palsy), but the number of cases was small, there was no adjustment for multiple testing, and the possible effect of residual unmeasured confounding in these analyses may have contributed to these findings.   This case was linked to US-MODERNATX, INC.-MOD-2023-731103 (Linked Report).; Sender's Comments: Company Comment: This is a literature non-study case concerning a patient of unknown age and gender, with no reported medical history, who experienced the serious (due to medically significant and hospitalization) unexpected, AESI of Pulmonary embolism, which occurred within 42 days after the first dose of mRNA-1273 vaccine. The outcome was not reported. No further clinical information was available for medical review. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. US-MODERNATX, INC.-MOD-2023-731103:First dose(Master case)